Research ExplorerPublicationsA post hoc analysis of long-term prognosis after exenatide t...

A post hoc analysis of long-term prognosis after exenatide treatment in patients with ST-segment elevation myocardial infarction

Standard

A post hoc analysis of long-term prognosis after exenatide treatment in patients with ST-segment elevation myocardial infarction. / Kyhl, Kasper; Lønborg, Jacob; Vejlstrup, Niels; Kelbæk, Henning; Helqvist, Steffen; Holmvang, Lene; Jørgensen, Erik; Saunamäki, Kari; Bøtker, Hans Erik; Clemmensen, Peter; Køber, Lars; Treiman, Marek; Engstrøm, Thomas.

In: EUROINTERVENTION, Vol. 12, No. 4, 20.07.2016, p. 449-455.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Kyhl, K, Lønborg, J, Vejlstrup, N, Kelbæk, H, Helqvist, S, Holmvang, L, Jørgensen, E, Saunamäki, K, Bøtker, HE, Clemmensen, P, Køber, L, Treiman, M & Engstrøm, T 2016, 'A post hoc analysis of long-term prognosis after exenatide treatment in patients with ST-segment elevation myocardial infarction', EUROINTERVENTION, vol. 12, no. 4, pp. 449-455. https://doi.org/10.4244/EIJV12I4A78

APA

Kyhl, K., Lønborg, J., Vejlstrup, N., Kelbæk, H., Helqvist, S., Holmvang, L., Jørgensen, E., Saunamäki, K., Bøtker, H. E., Clemmensen, P., Køber, L., Treiman, M., & Engstrøm, T. (2016). A post hoc analysis of long-term prognosis after exenatide treatment in patients with ST-segment elevation myocardial infarction. EUROINTERVENTION, 12(4), 449-455. https://doi.org/10.4244/EIJV12I4A78

Vancouver

Kyhl K, Lønborg J, Vejlstrup N, Kelbæk H, Helqvist S, Holmvang L et al. A post hoc analysis of long-term prognosis after exenatide treatment in patients with ST-segment elevation myocardial infarction. EUROINTERVENTION. 2016 Jul 20;12(4):449-455. https://doi.org/10.4244/EIJV12I4A78

Bibtex

@article{a247634d7ce14827b76de75e7192a441,
title = "A post hoc analysis of long-term prognosis after exenatide treatment in patients with ST-segment elevation myocardial infarction",
abstract = "AIMS: We aimed to assess the effect of exenatide treatment as an adjunct to primary percutaneous coronary intervention (PCI) on long-term clinical outcome.METHODS AND RESULTS: We performed a post hoc analysis in 334 patients with a first STEMI included in a previous study randomised to exenatide (n=175) or placebo (n=159) as an adjunct to primary PCI. The primary endpoint was a composite of all-cause mortality and admission for heart failure during a median follow-up of 5.2 years (interquartile range: 5.0-5.5). Secondary endpoints were all-cause mortality and admission for heart failure, individually. The primary composite endpoint occurred in 24% in the exenatide group versus 27% in the placebo group, p=0.44 (HR 0.80, p=0.35). Admission for heart failure was lower in the exenatide (11%) compared to the placebo group (20%) (HR 0.53, p=0.042). All-cause mortality occurred in 14% in the exenatide group versus 9% in the placebo group (HR 1.45, p=0.20).CONCLUSIONS: In this post hoc analysis of patients with a STEMI, treatment with exenatide at the time of primary PCI did not reduce the primary composite endpoint or the secondary endpoint of all-cause -mortality. However, exenatide treatment reduced the incidence of admission for heart failure.",
keywords = "Adult, Aged, Aged, 80 and over, Electrocardiography/methods, Exenatide, Female, Heart Failure/epidemiology, Humans, Male, Middle Aged, Myocardial Infarction/epidemiology, Peptides/therapeutic use, Percutaneous Coronary Intervention/methods, Platelet Aggregation Inhibitors/therapeutic use, Prognosis, Treatment Outcome, Venoms/therapeutic use",
author = "Kasper Kyhl and Jacob L{\o}nborg and Niels Vejlstrup and Henning Kelb{\ae}k and Steffen Helqvist and Lene Holmvang and Erik J{\o}rgensen and Kari Saunam{\"a}ki and B{\o}tker, {Hans Erik} and Peter Clemmensen and Lars K{\o}ber and Marek Treiman and Thomas Engstr{\o}m",
year = "2016",
month = jul,
day = "20",
doi = "10.4244/EIJV12I4A78",
language = "English",
volume = "12",
pages = "449--455",
journal = "EUROINTERVENTION",
issn = "1774-024X",
publisher = "EUROPA EDITION",
number = "4",

}

RIS

TY - JOUR

T1 - A post hoc analysis of long-term prognosis after exenatide treatment in patients with ST-segment elevation myocardial infarction

AU - Kyhl, Kasper

AU - Lønborg, Jacob

AU - Vejlstrup, Niels

AU - Kelbæk, Henning

AU - Helqvist, Steffen

AU - Holmvang, Lene

AU - Jørgensen, Erik

AU - Saunamäki, Kari

AU - Bøtker, Hans Erik

AU - Clemmensen, Peter

AU - Køber, Lars

AU - Treiman, Marek

AU - Engstrøm, Thomas

PY - 2016/7/20

Y1 - 2016/7/20

N2 - AIMS: We aimed to assess the effect of exenatide treatment as an adjunct to primary percutaneous coronary intervention (PCI) on long-term clinical outcome.METHODS AND RESULTS: We performed a post hoc analysis in 334 patients with a first STEMI included in a previous study randomised to exenatide (n=175) or placebo (n=159) as an adjunct to primary PCI. The primary endpoint was a composite of all-cause mortality and admission for heart failure during a median follow-up of 5.2 years (interquartile range: 5.0-5.5). Secondary endpoints were all-cause mortality and admission for heart failure, individually. The primary composite endpoint occurred in 24% in the exenatide group versus 27% in the placebo group, p=0.44 (HR 0.80, p=0.35). Admission for heart failure was lower in the exenatide (11%) compared to the placebo group (20%) (HR 0.53, p=0.042). All-cause mortality occurred in 14% in the exenatide group versus 9% in the placebo group (HR 1.45, p=0.20).CONCLUSIONS: In this post hoc analysis of patients with a STEMI, treatment with exenatide at the time of primary PCI did not reduce the primary composite endpoint or the secondary endpoint of all-cause -mortality. However, exenatide treatment reduced the incidence of admission for heart failure.

AB - AIMS: We aimed to assess the effect of exenatide treatment as an adjunct to primary percutaneous coronary intervention (PCI) on long-term clinical outcome.METHODS AND RESULTS: We performed a post hoc analysis in 334 patients with a first STEMI included in a previous study randomised to exenatide (n=175) or placebo (n=159) as an adjunct to primary PCI. The primary endpoint was a composite of all-cause mortality and admission for heart failure during a median follow-up of 5.2 years (interquartile range: 5.0-5.5). Secondary endpoints were all-cause mortality and admission for heart failure, individually. The primary composite endpoint occurred in 24% in the exenatide group versus 27% in the placebo group, p=0.44 (HR 0.80, p=0.35). Admission for heart failure was lower in the exenatide (11%) compared to the placebo group (20%) (HR 0.53, p=0.042). All-cause mortality occurred in 14% in the exenatide group versus 9% in the placebo group (HR 1.45, p=0.20).CONCLUSIONS: In this post hoc analysis of patients with a STEMI, treatment with exenatide at the time of primary PCI did not reduce the primary composite endpoint or the secondary endpoint of all-cause -mortality. However, exenatide treatment reduced the incidence of admission for heart failure.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Electrocardiography/methods

KW - Exenatide

KW - Female

KW - Heart Failure/epidemiology

KW - Humans

KW - Male

KW - Middle Aged

KW - Myocardial Infarction/epidemiology

KW - Peptides/therapeutic use

KW - Percutaneous Coronary Intervention/methods

KW - Platelet Aggregation Inhibitors/therapeutic use

KW - Prognosis

KW - Treatment Outcome

KW - Venoms/therapeutic use

U2 - 10.4244/EIJV12I4A78

DO - 10.4244/EIJV12I4A78

M3 - SCORING: Journal article

C2 - 27436599

VL - 12

SP - 449

EP - 455

JO - EUROINTERVENTION

JF - EUROINTERVENTION

SN - 1774-024X

IS - 4

ER -